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Introduction
Loop excision biopsy, also known as LLETZ
(large loop excision of the transformation zone), is
the most common and popular method of treatment
of cervical intraepithelial neoplasia (CIN). Loop bio-
psies are performed for both diagnostic and thera-
peutic purposes. The histological evaluation of the
loop excision biopsy specimen takes into account the
grade of CIN, the status of the margins of resection,
the presence or absence of CIN in endocervical
crypts, the presence or absence of invasion and cervi-
cal glandular intraepithelial neoplasia, and any other
associated pathology. The factors that have been
associated with the failure of treatment or recurrence
of CIN include the presence of CIN at ectocervical
and endocervical margins of resection, involvement
of endocervical glands, large CIN lesions, depth of
the loop, high grade of CIN, and the age of the
patient. The development of invasive carcinoma fol-
lowing treatment by loop excision biopsy is conside-
red a failure of treatment. No biological markers or
technologies useful to predict the natural history of
an individual CIN III are known. The probability of
progression is considered greater with the persistence
of high-risk human papillomavirus (HPV) infection
and age. In this study we evaluate the human papillo-
mavirus deoxyribonucleic acid testing  after coniza-
tion with reference to the prediction of residual disea-
se.
Materials and methods
The present study deals with 58 patients who were
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The development of invasive carcinoma following treatment by loop excision
biopsy is considered a failure of treatment
In this study we evaluate human papillomavirus deoxyribonucleic acid
testing  after conization in predicting residual disease.
In 56 of 58 patients (96.6%), HPV DNAs were detected in their pri-
mary cervical lesions prior to conization.
Up to August 2000, all of the 58 patients have been followed with a mean
follow-up period of 31.8 months (range: 12 to 73 months). 
After treatment, HPV DNA was persistently detected in 11 (19.6%) but
negative in 45 (80.4%) of 56 HPV DNA-positive patients.
Five of 11 persistently HPV DNA-positive patients (45.5%) developed
CIN recurrence, while none of 45 persistently HPV DNA-negative patients
did.
This  study confirms an exellent sensitivity and negative predictive value of
HPV-DNA testing after conization in predicting residual cervical neoplasia.
RIASSUNTO: Associazione tra presenza HPV e malattia resi-
dua dopo conizzazione.
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La  presenza di malattia residua dopo conizzazione è considerata un fal-
limento del trattamento. 
In questo studio il test per la ricerca dell’HPV dopo conizzazione è stato
utilizzato per predire  la presenza di malattia residua. 
In 56 delle 58 donne valutate (96,6%) è stata riscontrata la presenza di
HPV nella lesione primaria,  prima della conizzazione. 
Fino all’agosto 2000, tutte le 58 donne sono state sottoposte  ad un perio-
do di follow-up di 31,8 mesi (il range variava dai 12 ai 73 mesi).
Dopo il trattamento, la ricerca dell’HPV-DNA  è risultata positiva  in
11 casi (19,6%) e negativa in  45 delle 56 pazienti HPV-DNA positive.
In 5 delle 11 pazienti (45,5%) positive per l’HPV-DNA si è sviluppa-
ta una CIN, mentre in nessuna delle 45 pazienti risultate negative per
l’HPV-DNA  è stata riscontrata una ricorrenza di malattia.
Questo studio conferma l’alta sensibilità e il valore predittivo negativo
dell’HPV-DNA test dopo  conizzazione per predire la malattia residua.
KEY WORDS:  Conization - HPV-DNA testing - Residual disease.
Test per la ricerca all’HPV-DNA - Malattia residua.
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tested for HPV DNA in the pre-treatment cervical
lesions, out of the 74 who referred with CIN 3. After
standard therapeutic conization, patients were fol-
lowed prospectively at the outpatient clinic. Our fol-
low-up protocol was to follow patients without thera-
peutic intervention as long as they developed no
recurrence or recurrence of CIN 1 or 2; while patients
who experienced recurrence of CIN 3 were recom-
mended reconization or hysterectomy. The polymera-
se chain reaction for detecting HPV DNA was
performed using fresh cell samples from the cervix. 
Results
In 56 out of the 58 patients (96.6%), HPV DNAs
were detected in their primary cervical lesions prior to
conization. With regard to the distribution of HPV
types, HPV type 16 family (types 16, 31, and 35) was
identified in 28 cases (50.0%), type 18 family (types
18, 33 and 58) in 15 (26.8%), and type X in 18
(32.1%).  Up to August 2000, all the 58 patients were
followed-up for a mean period of 31.8 months (range:
12 to 73 months). After treatment, HPV DNA was
persistently detected in 11 (19.6%) of the 56 HPV
DNA-positive patients, but 45 (80.4%) of them were
found HPV DNA- negative. HPV DNA was not
detected in both HPV DNA-negative patients. Five of
the 11 persistently HPV DNA-positive patients
(45.5%) developed CIN recurrence, while none of the
45 persistently HPV DNA-negative patients did.
Thus, there was a significant difference between the
recurrence rates of these two groups (P < 0.0001).
Both patients who were initially HPV DNA-negative
developed no recurrence. Accordingly, the overall
recurrence following conservative treatment for CIN
3 was 5 patients out of 58 (8.6%). 
Discussion and conclusions
Persistent HPV infection appears to be a clear risk
factor for persistent cervical intraepithelial neoplasia
(CIN II) and type-specific persistence of high-risk
HPV infection is a good predictor of the possibility
of developing high-grade lesions. HPV seems to be a
stronger predictor of persistent cervical abnormalities
in women over 35. Certain types of HPV and persi-
stent high loads of viral infection may be associated
with increased risks of cervical neoplasia, but whether
this justifies HPV DNA screening is still open to
debate. HPV remains detectable longer than cervical
cytologic abnormalities, suggesting that HPV DNA
testing may be a more sensitive test for HPV infec-
tion and that there may be a role for HPV- DNA
testing in women with ambiguous cytology results.
Women treated for CIN2 or CIN3 remain at increa-
sed risk of cervical cancer for at least 8 years in com-
parison with the general population. Generally, cyto-
logy and/or colposcopy have been used for post-
treatment surveillance. HPV testing deserves investi-
gation as another possible strategy to monitor the
efficacy of the treatment. Several small studies have
shown that HPV DNA clearance is associated with
low risk of subsequent CIN after treatment, and per-
sistent HPV positivity predicts increased risk of treat-
ment failure. However, the possibility of vaginal reco-
lonization with HPV or a new HPV infection with
another HPV type must be considered. This  study
confirms the excellent sensitivity and negative predic-
tive value of HPV-DNA testing after conization as far
as the prediction of residual cervical neoplasia is con-
cerned. Patients with persistent HPV infection after
conization for CIN 3 should be closely followed
because they are at increased risk of developing disea-
se recurrence.
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